Rifapentine (Priftin) coverage and PA criteria
Customize your policy alerts
Sign up for Arizona Complete Health Policy AZ.CP.PMN.05 alerts
Get alerted when Policy AZ.CP.PMN.05 changes without checking for updates manually.
Monitor payer policy activity
Defines medical necessity, prior authorization, dosing, and coverage criteria for rifapentine (Priftin) for treatment of active pulmonary tuberculosis and latent tuberculosis infection for Arizona Complete Health members.
For active pulmonary TB added requirements for optional 4 month daily Priftin regimen prescribed in combination with isoniazid, moxifloxacin, and pyrazinamide as well as maximum dosing requirements; added option for HIV-positive use requiring CD4 count ≥ 100 cells/mm3.
For latent TB modified isoniazid trial duration from 9 to 6 months per CDC and WHO treatment guidelines.
For latent TB added bypass for isoniazid redirection and optional alternative dosing up to 600 mg/day for a 4 week regimen per NIH/CDC HIV guidelines.
Removed reference to retired policy AZ.CP.PMN.53 Off-Label Use policy and added AHCCCS FFS Prior Authorization Guideline - Coverage of Off-Label Non-FDA Approved Indications.
Removed reference to Care1st Health plan and logos.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.